Ovary Removal Before Menopause Linked to Cognitive Impairment, Dementia Risk

Translate to Spanish or other 102 languages!

A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes
A new study shows that ovary removal before menopause is linked to decreased white matter in the brain later in life. Image for illustration purposes
- Advertisement -
  • A new study examined the brains of females who underwent full ovary removal before going through menopause.
  • Sometimes, females must undergo this type of procedure to treat conditions such as ovarian cancer or endometriosis.
  • The study’s findings show that females who undergo ovary removal before menopause have a decrease in white matter in their brains later in life. 
  • A decrease in white matter is linked to cognitive impairment.

A new study examined the cognitive effects of ovary removal in females.

Follow the link below to Medical News Today to read the full story:

https://www.medicalnewstoday.com/articles/ovary-removal-before-menopause-cognitive-decline-dementia-risk?slot_pos=article_2&utm_source=Sailthru%20Email&utm_medium=Email&utm_campaign=MNT%20Daily%20News&utm_content=2024-06-28&apid=&rvid=4ba4ec80177cae00eabc43b8bc6648d598c4a356d104663735777e0a0f8b5c9f

- Advertisement -

Information Source: https://www.medicalnewstoday.com

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

How Dogs Benefit Mind and Soul

"Dogs are wonderful greeters. They're waiting for you to come home, and they're always happy to see you. In turn, this increases our feel-good hormones, like dopamine and serotonin,” explained Chivonna Childs, PhD.

Data Reveals US Illicit Fentanyl Use is Double That of Clinical Care

The largest study to date that quantifies and compares medical and illegal use of fentanyl in the United States suggests that illicit use is more than twice as common as medically based use. 

7 Crucial Caregiving Truths Families Often Overlook

If you clicked to read this story, or someone sent it to you, congratulations: You’re a caregiver.

Moderna and Merck Report Positive Phase 3 Results for Personalized Cancer Therapy

Moderna and Merck have reached a major clinical milestone after their investigational individualized cancer therapy, combined with Merck’s Keytruda, produced positive results in a Phase 3 study involving patients with high-risk melanoma.
- Advertisement -